Article Information
History
- August 19, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Marilia Santini-Oliveira1,
- Patrícia Machado Pinto2,
- Tatiane dos Santos2,
- Monica Magno Vilar2,
- Beatriz Grinsztejn1,
- Valdilea Veloso1,
- Elan C. Paes-de-Almeida3,
- Maria A. Z. Amaral4,
- Celso R. Ramos5,
- Miryam Marroquin-Quelopana5,
- Rhea Coler6,
- Steven Reed7,
- Marcia Ciol8,
- Wilson Savino9,10,
- Juçara de Carvalho Parra11,
- Marília Sirianni dos Santos Almeida2 and
- Miriam Tendler2,*
- 1Evando Chagas National Institute of Infectology, Fiocruz, Rio de Janeiro, 21045-900, Brazil
- 2Laboratory of Experimental Schistosomiasis, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Av. Brasil, n°4365, Manguinhos, 21045-900, Rio de Janeiro, Brazil
- 3Department of Basic Sciences, Fluminense Federal University, Nova Friburgo, RJ, Brazil
- 4Program for Development of the Mata Atlântica Campus, Fiocruz, Rio de Janeiro, Brazil
- 5Fenix Biotec Treinamento SS LTDA, São Paulo, Brazil
- 6Department of Global Health, University of Washington, Seattle, USA
- 7HDT Bio, Seattle, USA
- 8Department of Rehabilitation Medicine, School of Medicine, University of Washington, Seattle, USA
- 9Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
- 10Brazilian National Institute of Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
- 11René Rachou Institute — Fiocruz Minas, Oswaldo Cruz Foundation, Belo Horizonte, Brazil
- ↵*Corresponding author: E-mail address: mtendler{at}ioc.fiocruz.br; tendlermiriam{at}gmail.com (MT)
Posted August 19, 2022.
Development of the Sm14/GLA-SE - schistosomiasis vaccine candidate: An open, not placebo-controlled, standardized dose immunization phase Ib clinical trial targeting healthy young women
